{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Overall survival was defined as the duration from the start of study treatment to the date of death from any cause.","groups":[{"description":"Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.","id":"OG000","title":"Part 2: PF-07263689 + Sasanlimab"}],"populationDescription":"Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.","reportingStatus":"POSTED","timeFrame":"From start of study treatment to the date of death from any cause (up to 2 years)","title":"Part 2: Overall Survival","type":"SECONDARY"}